Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Acetonemia

glucose, (beta-d)-isomer has been researched along with Acetonemia in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.55)29.6817
2010's14 (63.64)24.3611
2020's7 (31.82)2.80

Authors

AuthorsStudies
Cerone, SI; García, MC; Sansinanea, AS1
Seki, H; Watanabe, H; Yorozu, T1
Cardinez, N; Eldelekli, D; Falappa, CM; Ghanbari, M; Gouchie-Provencher, N; Haidar, A; Jafar, A; Lovblom, LE; Orszag, A; Perkins, BA; Rutkowski, J; Tsoukas, MA; Yale, JF1
Fu, Z; Husain, M; Ilkayeva, O; Inzucchi, SE; Javaheri, A; Jones, P; Kosiborod, MN; Kwee, LC; Lanfear, DE; Margulies, KB; McGuire, DK; Mentz, RJ; Nassif, ME; Newgard, CB; Pitt, B; Scirica, BM; Selvaraj, S; Shah, SH; Windsor, SL1
Iizuka, K; Kato, T; Liu, Y; Mizuno, M; Nonomura, K; Takao, K; Yabe, D; Yasuda, M1
Fourlanos, S; Neoh, SL; Nolan, BJ; Varadarajan, S1
Bolli, GB; Fanelli, CG; Lucidi, P; Porcellati, F1
Davies, M; Fielding, BA; Garesse, R; Herring, RA; Jackson, N; Johnsen, S; Mendis, A; Russell-Jones, DL; Shojaee-Moradie, F; Stevenage, M; Umpleby, AM1
Fukagawa, M; Miyauchi, M; Toyoda, M1
Breuer, TGK; Kampmann, K; Meier, JJ; Schmidt, WE; Steinfort, C; Uhl, W; Wutzler, A1
Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS1
Chan, MJ; Hsu, CW; Huang, WH; Weng, CH; Yen, TH1
Chua, CL; Lim, GJ; Low, SKM; Shao, Y; Sum, CF; Wong, YF; Yeoh, ECK1
Inzucchi, SE; Lupsa, BC1
Han, S; Jin, K; Paek, JH; Park, H; Park, SB; Park, WY; Yeo, SM1
Cardone, RL; Kibbey, RG; Perry, RJ; Rabin-Court, A; Shulman, GI; Song, JD; Wang, Y1
Aharon-Hananel, G; Raz, I1
Araki, E; Iwamoto, Y; Kaku, K; Suganami, H; Tanizawa, Y; Terauchi, Y; Tobe, K; Ueda, M; Utsunomiya, K; Watada, H; Watanabe, D1
Ghosh, A; Gupta, R; Misra, A1
Faillie, JL1
Scheen, AJ1

Reviews

3 review(s) available for glucose, (beta-d)-isomer and Acetonemia

ArticleYear
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Diabetologia, 2018, Volume: 61, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
Pharmacological aspects of the safety of gliflozins.
    Pharmacological research, 2017, Volume: 118

    Topics: Animals; Benzhydryl Compounds; Fractures, Bone; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Lipids; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors

2017
SGLT2 Inhibitors: Benefit/Risk Balance.
    Current diabetes reports, 2016, Volume: 16, Issue:10

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ketosis; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors

2016

Trials

2 trial(s) available for glucose, (beta-d)-isomer and Acetonemia

ArticleYear
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
    Nature medicine, 2022, Volume: 28, Issue:6

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Ketosis; Treatment Outcome

2022
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative
    Cardiovascular diabetology, 2014, Mar-28, Volume: 13

    Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult

2014

Other Studies

17 other study(ies) available for glucose, (beta-d)-isomer and Acetonemia

ArticleYear
Effects of beta-hydroxybutyric acid on bovine milk leukocytes function in vitro.
    General physiology and biophysics, 2007, Volume: 26, Issue:1

    Topics: 3-Hydroxybutyric Acid; Animals; Cattle; Female; Hydrogen Peroxide; Ketone Bodies; Ketosis; Leukocytes; Macrophages; Milk; Neutrophils; Nitroblue Tetrazolium; Phagocytosis; Tetradecanoylphorbol Acetate; Zymosan

2007
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report.
    A&A practice, 2022, Mar-09, Volume: 16, Issue:3

    Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis

2022
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Circulation, 2022, 09-13, Volume: 146, Issue:11

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiomyopathies; Fatty Acids; Female; Glucosides; Heart Failure; Humans; Ketones; Ketosis; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left

2022
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:3

    Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sarcopenia; Sodium-Glucose Transporter 2 Inhibitors

2020
Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
    The American journal of medicine, 2020, Volume: 133, Issue:8

    Topics: Aged; Autoantibodies; Benzhydryl Compounds; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketosis; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2020
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
    Diabetes care, 2021, Volume: 44, Issue:3

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors

2021
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
    Diabetes care, 2021, Volume: 44, Issue:3

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors

2021
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:13

    Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult

2017
[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].
    Der Internist, 2018, Volume: 59, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Critical Care; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fluid Therapy; Glucosides; Humans; Ketosis; Sodium-Glucose Transporter 2 Inhibitors

2018
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
    Diabetes & metabolism, 2018, Volume: 44, Issue:1

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Ketosis; Middle Aged; Young Adult

2018
Dapagliflozin associated ketoacidosis: A must know fact for nephrologists.
    Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:2

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus; Female; Glucosides; Humans; Ketosis; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2018
The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes.
    Diabetes research and clinical practice, 2018, Volume: 142

    Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Fasting; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Islam; Ketosis; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2018
Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
    Medicine, 2019, Volume: 98, Issue:3

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Ketosis; Renal Replacement Therapy; Saline Solution; Sodium Bicarbonate; Young Adult

2019
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
    Nature communications, 2019, 02-01, Volume: 10, Issue:1

    Topics: Animals; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucocorticoids; Glucose; Glucosides; Humans; Insulin; Ketosis; Lipolysis; Liver; Male; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1; Sodium-Glucose Transporter 2 Inhibitors

2019
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemia; Ketosis; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2019
In brief: ketoacidosis with SGLT2 inhibitors.
    The Medical letter on drugs and therapeutics, 2015, Jun-22, Volume: 57, Issue:1471

    Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sodium-Glucose Transporter 2 Inhibitors

2015
Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Journal of diabetes, 2016, Volume: 8, Issue:5

    Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Ketosis; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016